Genzyme and Veracyte in personalised medicine tie-up for thyroid cancer
This article was originally published in Scrip
Executive Summary
Sanofi's Genzyme and molecular diagnostics company Veracyte have entered into a global co-promotion agreement that taps into Genzyme's endocrinology sales force and marketing infrastructure to help speed up commercialisation of Veracyte's diagnostic technology in order to provide a personalised medicine 'solution' for the diagnosis and treatment of thyroid cancer.